1. Efficacy and safety of homoharringtonine plus cytarabine and aclarubicin for patients with myelodysplastic syndrome-RAEB.
- Author
-
FENG XIAO, YING LI, WEILAI XU, LIANGSHUN YOU, CHUNMEI YANG, HUI LIU, and WENBIN QIAN
- Subjects
CYTARABINE ,MYELODYSPLASTIC syndromes ,DRUG efficacy ,MEDICATION safety ,TREATMENT effectiveness ,PATIENTS - Abstract
The aim of the present study was to evaluate the treatment outcome of homoharringtonine, cytarabine (AraC) and aclarubicin combination therapy as induction treatment for myelodysplastic syndromes-refractory anemia with excess blasts (MDS-RAEB). A total of 24 patients with MDS-RAEB who were aged between 18 and 66 years were treated with homoharringtonine, AraC and aclarubicin (HAA regimen). The HAA regimen consisted of homoharringtonine (2 mg/m² intramuscularly twice daily, days 1-3), AraC (75 mg/m² injected subcutaneously twice daily, days 1-7) and aclarubicin (12 mg/m², days 1-7). The overall response rate was 79% with a complete remission rate of 58.3% and partial remission rate of 20.7%. There was no evidence of early mortality in this group of patients. The median overall survival (OS) was 36.2 months (95% confidence interval, 24.6-47.4 months), and the estimated three year overall survival rate was 45.8%. In conclusion, HAA combination therapy is a suitable induction regimen for patients with MDS-RAEB, which may improve the outcome for de novo higher-risk MDS patients, particularly of those with favorable and intermediate cytogenetics. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF